Sean Stanton

Biography

 enior Vice President Global Operations, Research Network Sean is a senior life science executive who has dedicated the last 25 years of his career to creating successful, high-performing research sites. To date, Sean has led the start-up of 25 clinical trial sites, six inpatient hospitals, and 19 outpatient clinics. More than 5,000 clinical trials have been conducted at these sites, leading to more than 50 drug approvals. Prozac was the first approved drug Sean worked on, followed by many other well-known drugs used in a variety of therapeutic areas (e.g., General Medicine, Vaccine, Women’s Health, Diabetes; Pain; Mental Health; Heart Disease; Oncology; Neurodegenerative Diseases; Sleep Disorders; etc.). In these trials Sean directed recruitment for the screening of 2,000 to 6,000 patients annually. A pioneer in patient recruitment, Sean was the first to pre-screen for screens and was on the forefront of direct-to consumer advertising, circa 1997. Sean has brought innovative thinking to clinical research in all aspects of site practices, from purchasing and resourcing, to the use of benchmarking and metrics in business planning to guide strategic clinical trial practice growth. Sean is frequently sought as an industry expert to speak on topics including building successful clinical research sites; patient recruiting, particularly difficult to recruit populations and decreasing screen fail rates; protocol design; site selection; patient reported outcomes and other areas. He has advised hospitals and institutions on research site growth strategy and mergers and acquisitions at the site level.

Research Interest

 Molecular and Cell Biology